These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10976450)

  • 21. A model-free approach to estimation of relative potency in dose-response curve analysis.
    Guardabasso V; Rodbard D; Munson PJ
    Am J Physiol; 1987 Mar; 252(3 Pt 1):E357-64. PubMed ID: 3826362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Different Estimation Methods for Accuracy and Precision in Biological Assay Validation.
    Yu B; Yang H
    PDA J Pharm Sci Technol; 2017; 71(4):297-305. PubMed ID: 28416644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of optimal dose.
    Khan MK; Khan MA
    Comput Biomed Res; 1985 Apr; 18(2):193-203. PubMed ID: 3987233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporating extra information in experimental design for bioassay.
    Nordheim EV; Tsiatis A; Shapas TJ
    Biometrics; 1983 Mar; 39(1):87-96. PubMed ID: 6871365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the statistical analysis of bioassays.
    Wong MY
    Comput Methods Programs Biomed; 1996 May; 49(3):191-7. PubMed ID: 8800606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.
    DeLean A; Munson PJ; Rodbard D
    Am J Physiol; 1978 Aug; 235(2):E97-102. PubMed ID: 686171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The design and analysis of experiments for the assessment of drug interactions.
    Mitchell CL
    Ann N Y Acad Sci; 1976; 281():118-35. PubMed ID: 798519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum.
    Wei X; Grill DS; Heatherington AC; Swanson SJ; Gupta S
    J Pharm Biomed Anal; 2007 Jan; 43(2):666-76. PubMed ID: 16971087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model uncertainty and risk estimation for experimental studies of quantal responses.
    Bailer AJ; Noble RB; Wheeler MW
    Risk Anal; 2005 Apr; 25(2):291-9. PubMed ID: 15876205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-parametric interval estimation of relative potency for dilution assays, including the case of non-monotone dosage response curves.
    Mantel N; Schneiderman MA
    Biometrics; 1975 Sep; 31(3):619-32. PubMed ID: 1174621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of number of doses for maximum likelihood estimation of the ED50 for quantal dose-response data.
    Müller HG; Schmitt T
    Biometrics; 1990 Mar; 46(1):117-29. PubMed ID: 2350566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian model-averaged benchmark dose analysis via reparameterized quantal-response models.
    Fang Q; Piegorsch WW; Simmons SJ; Li X; Chen C; Wang Y
    Biometrics; 2015 Dec; 71(4):1168-75. PubMed ID: 26102570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical inference for relative potency in bivariate dose-response assays with correlated responses.
    Iturria SJ
    J Biopharm Stat; 2005; 15(2):343-51. PubMed ID: 15796299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical analysis of drug interactions.
    Mitchell CL
    NIDA Res Monogr; 1986; 68():41-64. PubMed ID: 3095655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equivalence testing for parallelism in the four-parameter logistic model.
    Jonkman JN; Sidik K
    J Biopharm Stat; 2009 Sep; 19(5):818-37. PubMed ID: 20183446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical models for quantitative bioassay.
    Facer MR; Müller HG; Clifford AJ
    Adv Exp Med Biol; 1998; 445():147-71. PubMed ID: 9781388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simple designs and model-free tests for synergy.
    Laska EM; Meisner M; Siegel C
    Biometrics; 1994 Sep; 50(3):834-41. PubMed ID: 7981403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outlier robust nonlinear mixed model estimation.
    Williams JD; Birch JB; Abdel-Salam AS
    Stat Med; 2015 Apr; 34(8):1304-16. PubMed ID: 25581342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A personal view of pharmacology.
    Black J
    Annu Rev Pharmacol Toxicol; 1996; 36():1-33. PubMed ID: 8725380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-time-response cumulative multinomial generalized linear model.
    Chen DG
    J Biopharm Stat; 2007; 17(1):173-85. PubMed ID: 17219762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.